This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, 1 with approximately 500,000 new cases per year. Approximately 80% of cases arise in Asia and Africa, 2 mainly due to chronic hepatitis B virus (HBV) infection. The incidence of HCC is rising in the United States and Europe because of increased incidence of hepatitis C (HCV) infection. 3 Surgical resection and liver transplantation are considered the only cures for HCC, but benefit only approximately 15% of patients. 4 Unresectable or metastatic disease patients have median survival of a few months. 5 There is a substantial need for novel treatments for advanced HCC, because systemic therapy induces relatively few responses and has no clear survival benefit.
Preclinical studies demonstrated that Raf/ MAPK-ERK kinase (MEK)/extracellular signal regulated kinase (ERK) pathway has a role in HCC. 6 Furthermore, over-expression of activated MEK1 in HCC cell lines enhanced tumor growth and survival by preventing apoptosis. HCV core proteins elicit high basal Raf-1 activity in hepatocytes, increasing the risk of neoplastic transformation.
7,8 HCC tumors are highly vascularized, and vascular endothelial growth factor (VEGF) augments HCC development and metastasis. 9 Therefore, blocking signaling through Raf-1 may offer therapeutic benefits in HCC. 6 Sorafenib, an oral multikinase inhibitor, blocks tumor cell proliferation by targeting Raf/MEK/ERK signaling at the level of Raf kinase, and exerts an antiangiogenic effect by targeting vascular endothelial growth factor receptor-2/-3 (VEGFR-2/-3), and platelet derived growth factor receptor beta (PDGFR-␤) tyrosine kinases.
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In a phase I trial of sorafenib, a confirmed partial response was observed in a metastatic HCC patient.
11 This response, and the importance of VEGF and Raf/MEK/ERK signaling in HCC, prompted this phase II study to evaluate further the efficacy, toxicity, and pharmacokinetics (PK) of sorafenib in advanced HCC. The predictive value of molecular biomarkers in determining time to progression (TTP) was also evaluated.
METHODS
This was a multicenter, international, uncontrolled phase II trial in advanced HCC patients. The trial was approved by a human investigation committee at each center, and conducted in accordance with the US Dept of Health and Human Services guidelines. Informed consent was obtained from each patient.
Patients' Eligibility
Patients with measurable, histologically proven, inoperable HCC who had not received prior systemic treatments for HCC were eligible for enrollment. Inclusion criteria included Eastern Cooperative Oncology Group performance status of 0 or 1; Child-Pugh (CP) score of A or B; life expectancy of at least 12 weeks; elevated alphafetoprotein (AFP) level and adequate hematologic, hepatic, and renal function. HBV or HCV infection status at baseline was collected from medical history or laboratory tests.
Patients with tumors of mixed histology or fibrolamellar variant, pregnant or lactating women, or those requiring systemic anticancer therapy, biologic-response modifiers, or CYP34A inhibitors or with medical/psychological/social problems that might affect study participation or evaluations were excluded.
Treatment and Dose Modifications
Patients received sorafenib 400 mg bid, but were allowed up to two dose reductions (200 mg bid and 200 mg qd) for drug-related toxicities (National Cancer Institute [Bethesda, MD] Common Toxicity Criteria v2.0). Otherwise, treatment continued until disease progression (PD) or unacceptable drugrelated toxicities.
Dose delays or modifications were required for drug-related toxicities. For grade 3/4 toxicities; patients received lower doses when toxicity improved to grade 2 or better, but therapy was discontinued if recovery time was 3 weeks or longer. A dose delay was introduced for grade 3 nonhematologic toxicities, until toxicity was grade 2 or better; patients were then treated at one dose level lower, and therapy was discontinued if recovery time was 3 weeks or longer. Patients with drug-related grade 4 nonhematologic toxicities were treated at two dose levels lower at the first appearance and withdrawn at the second. A modified scale was used for hand-foot skin reaction (HFS), to facilitate interpretation (Table 1) , and specific dose modifications were implemented (Table 2) .
Response Assessment
Investigator-assessed bidimensional tumor measurements were performed at baseline and every 8 weeks (two cycles), according to modified WHO criteria. Independent radiologic assessment was also performed for patients who had baseline and at least one postbaseline imaging measurement. Stable disease (SD) was required to last at least 16 weeks. Throughout the study, lesions measured at baseline were evaluated using the same technique and, preferably, by the same investigator. Overall tumor response was scored as a complete response (CR), partial response (PR), or minor response (MR; a reduction in tumor size of Ն 25% but Ͻ 50% v baseline) if the response was confirmed at least 4 weeks later.
Secondary objectives were duration of response (first administration of study drug until PD in patients with objective responses); TTP (first administration of study drug until PD); duration of SD (first day of receiving sorafenib until PD or response); overall survival (first day of receiving study medication to death). Patients who received at least one dose of sorafenib and had posttreatment data available were assessable for overall response rate.
Assessing Tumor Necrosis
In addition to evaluation of tumor necrosis (TN) by independent radiologists, a semiautomated computerized technique quantified TN on intravenous contrast-enhanced scans in 11 of 16 patients accrued at Memorial SloanKettering Cancer Center (New York, NY). A dominant hepatic mass(es) was selected at baseline and followed every two cycles. Response assessment was calculated with uni-and bidimensional tumor measurements, and TN was calculated at each time point by a radiologist blinded to the clinical data.
PK
Blood samples were collected on day 1 of cycle 2 for PK analysis of sorafenib plasma concentrations using a validated liquid chromatography/ mass spectrometry/mass spectrometry assay, with a lower limit of quantification of 1 to 10 g/L. PK was assessed in 22 patients on or after 28 days of dosing. Samples were collected at 0 hours (predose), and 0.5, 1, 2, 4, 8, and 12 hours postdose. Parameters included area under the curve (AUC), maximum concentration (C max ), and time to maximum concentration (t max ). AUC over 8 hours (AUC 0-8 ) was determined, because 12-hour samples were not collected for most patients. Noncompartmental PK parameters were calculated using KinCalc software (Bayer AG, Wuppertal, Germany).
Biomarker Evaluation: Tumor-Cell Phosphorylated Extracellular Signal Regulated Kinase Levels
Sections (5 to 6 m thick) cut from paraffin-embedded tumor biopsies from 33 patients were analyzed with immunohistochemistry using a rabbit polyclonal antibody for phosphorylated extracellular signal regulated kinase (pERK) (phospho-p44/42 mitogen-activated protein kinase [Thr202/ Tyr204]; Cell Signaling Technology Inc, Danvers, MA). Positive and negative Painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient's activities Grade 3
Moist desquamation, ulceration, blistering or severe pain of the hands and/or feet, and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living controls ensured that the integrity of all tumor samples and reagents was maintained. Positive controls, selected because they encompass a range of pERK staining, included human xenograft MDA-MB-231 (breast) and MiaPaCa (pancreas) cells, and a renal cell carcinoma biopsy. Slides from each biopsy were stained with a species, isotype (immunoglobulin G) and concentration-matched negative control antibody. A hematoxylin-eosin slide was also stained for each sample. Stained slides were evaluated independently by two pathologists. Localization of pERK staining to cell nuclei or cytoplasm was evaluated qualitatively. Nuclear pERK staining intensity was graded semiquantitatively using a five-point scale: 0, no staining; 1ϩ, weak; 2ϩ, moderate; 3ϩ, strong and 4ϩ, intense. Tumor response and pERK staining were correlated using the Peto modification of the Gehan-Wilcoxon rank sum test.
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Biomarker Evaluation: Blood-Cell RNA Expression Patterns Blood samples were taken at baseline (within 7 days before treatment), on day 15 of cycle 1, day 1 of every second cycle (cycle 3, 5, 7 and so on) and at the final visit, and stored at Ϫ80°C. A modified Affymetrix (Santa Clara, CA) microarray technique was used to identify blood-cell RNA expression patterns that may predict clinical benefit from treatment. 13 Total RNA was isolated from blood samples using Qiagen QIAamp RNA Blood Mini kit and protocol (Qiagen Inc, Valencia, CA), and stored at Ϫ80°C. cDNA synthesis was performed with 500 ng-5 g RNA using Superscript Choice System (Invitrogen, Carlsbad, CA). In vitro transcription of cDNA using the BioArray HighYield Transcription kit (Enzo Diagnostics, Farmingdale, NY) generated cRNA for array analyses. HG-U133 Plus 2.0 arrays (containing Ͼ 60,000 probe sets, which represent 50,000 RNA transcripts) from Affymetrix were hybridized, washed, and stained with 6 g phycoerythrin-streptavidin (Molecular Probes, Carlsbad, CA). Affymetrix GeneChips were scanned at 488 nm by GeneChip Scanner 3000 and analyzed using Affymetrix MicroArray Suite 5.0 software. GeneChip data were used to develop mathematical models based on algorithms to predict TTP with sorafenib. Models were evaluated for predictive (estimated) accuracy using either 10-fold or leave-one-out cross validation.
14 The gene selection process was based on a data-mining technique called Support Vector Machine using investigator-assessed SD at 8 weeks, rather than 16 weeks used for efficacy end points, due to technical limitations.
Quality-control procedures ensured that deviations in sample collection, freezing, storage, and shipping were minimized, and that resulting cRNA was of suitable quality for analysis on Affymetrix GeneChips. From a total of 240 whole-blood samples, only 52 (representing 32 patients) yielded cRNA of sufficient quality.
Statistical Analysis
The study progressed using a three-stage design, recruiting a total of 26 stage 1, 71 stage 2, and 135 stage 3 patients. Two planned interim analyses were conducted after the availability of at least 3-month tumor response data from stages 1 and 2. Accrual was not held during interim analyses, and continued during the 3-month maturation of response data, thus accounting for the larger-than-planned accrual. Under the null hypothesis, the regimen would be rejected as a cytoreductive agent if confirmed response rate was 7% or less.
The first interim analysis considered the following: (a) 1 confirmed CR/PR; (b) 2 confirmed MRs; (c) 2 patients with at least 50% reduction in AFP; (d) 3 patients with either confirmed MRs or more than 50% reduction in elevated AFP or SD for 12 weeks. If none of these were met, the null hypothesis was accepted. If (a) was met, stage 2 could proceed. If (a) was not met but at least one of the other three conditions was met, stage 2 could proceed due to potential clinical benefit in the form of MRs, tumor marker reduction, and cytostatic and/or biomarker reduction. The first interim analysis suggested potential activity; therefore, patient enrollment was permitted to continue.
The second interim analysis considered the following: (a) If five or fewer patients had confirmed CR or PR, the null hypothesis was accepted; (b) If at least 11 patients had confirmed CR or PR, the null hypothesis was rejected; (c) If six to 10 patients responded, accrual proceeded to stage 3. Stage 3 would accrue a cumulative total of 135 and consider the following: (a) If 14 or fewer patients had confirmed PR/CR, the null hypothesis was accepted. Patient recruitment was placed on hold, at the outset of the second interim analysis, to complete statistical analysis; however, investigators were permitted to enroll patients who were already in the screening phase. Due to rapid multicenter accrual, at the accrual hold, 147 patients had been screened and were eligible for enrollment.
RESULTS

Demographics
The study enrolled 147 patients in Belgium, France, Italy, Israel, and the United States from August 2002 until June 2003, and all results are based on the treated population of 137 patients (Table 3) . Ten patients did not meet the inclusion/exclusion criteria, and were registered as screening failures. Twelve patients were still receiving treatment as of May 16, 2004 . Sixty-five percent had hepatitis B or C.
Dose and Duration of Therapy
Median study duration was 3.4 months (range, 0 to 17.4 months), median number of treatment cycles was four (range, 1 to 19), and 72% of patients (92 of 128 patients) received six or fewer treatment cycles. Of the 132 patients who discontinued, 79 were because of disease progression, 27 because of adverse events, and 11 died.
Efficacy
Independently assessed responses were as follows: three patients (2.2%) achieved PR, eight (5.8%) had MR, and 46 (33.6%) had SD (Ն 16 weeks; Table 4 ). Of the three patients who had independently confirmed PR, the duration of response ranged from 12.0 to 14.5 months. Responses based on investigator assessment were as follows: eight (5.8%) achieved PR, six (4.4%) had MRs, and 50 (36.5%) had SD (Ն 16 weeks).
Tumor Necrosis
Despite tumors' appearing to have grown, many patients' scans displayed central TN. TN was assessed more rigorously in 11 patients (Fig 1) . Tumors that increased in size (diameter and cross-product) demonstrated increases in TN. Baseline mean TN was 9.8% (range 0.4% to 33.5%), tumor diameter was 6.4 cm (range 2.5 to 14.2 cm), and cross-product was 28.9 cm 2 (range 5.3 to 91.3 cm 2 ). Follow-up mean TN was 27% (0.7% to 75%), tumor diameter was 7.2 cm (1.7 to 16.0 cm), and cross-product was 36.9 cm 2 (2.1 to 162.5 cm 2 ).
TTP and Survival
On the basis of investigator assessment, median TTP was 4.2 months (Fig 2) . On the basis of independent assessment, median TTP was 5.5 months (Fig 3) , and median overall survival was 9.2 months (Fig 4) .
Toxicity
The most common drug-related adverse events (any grade) were dermatologic, constitutional, and GI (Table 5) . Grade 3 toxicities included fatigue (9.5%), diarrhea (8.0%), and HFS (5.1%).
Sixty-day mortality was 10% of patients; 13 of 14 deaths within the first 60 days from starting therapy were related to PD. One death was secondary to an intracranial hemorrhage, but it is unclear whether it was drug related.
PK Data
There was some variability in AUC and C max values, which were slightly greater in CP B than in CP A groups (Table 6 ; Fig 5) . These differences were not considered significant.
Biomarker Evaluation: Tumor-Cell pERK Levels
Thirty-three patients had tissue available for tumor-cell pERK staining and comparative analyses. In the majority of tumor samples, staining was generally most intense within the nucleus of tumor cells (Fig 6) , and regional differences in the amount of staining were observed. There was a significant difference in TTP between patients with higher (2 to 4ϩ, n ϭ 18) tumor-cell pERK staining intensity, in archived specimens obtained before study treatment, versus those with lower intensity (0 to 1ϩ, n ϭ 15; P ϭ .00034; Figs 6 and 7). Patients with tumors expressing higher pERK staining intensity had a longer TTP. Levels of nonspecific background staining were very low, and were attributable to endogenous biotin, pigments, or residual peroxidase. There was also some evidence of pERK staining within most tumor samples, predominantly localized to the nuclei, in non-neoplastic cells including endothelial cells, fibroblasts, and lymphocytes.
Biomarker Evaluation: Blood-Cell RNA Expression Patterns
Twenty-one patients were initially evaluated for blood-cell RNA expression levels. A panel of 18 genes was identified whose expression distinguished "nonprogressors" (investigator assessed) from "progressors" with an estimated accuracy of 100% (Table 7 ). This panel of 18 genes was then used to predict, in a blinded manner, the status of an additional 10 patients (eight nonprogressors and two progressors) receiving sorafenib. The predictive accuracy of the panel was 100%, because the status of all 10 patients was predicted correctly.
DISCUSSION
In this phase II trial, sorafenib was generally well tolerated and demonstrated antitumor activity in advanced HCC patients. HCC is a highly resistant solid tumor, and HCC cells have been shown to overexpress the multidrug resistance gene 15 and gene product P-glycoprotein. 16 HCC is associated with upregulation of dihydropyrimidine dehydrogenase, and thus is potentially resistant to chemotherapies such as fluorouracil. 17, 18 With the development of novel targeted therapies, there is an opportunity to evaluate these agents in HCC. 19 Sorafenib demonstrated a median overall survival of 9.2 months, with 34% of patients achieving SD for at least 16 weeks and 8% achieving PRs or MRs. These data compare favorably with single-arm studies evaluating combination therapy (cisplatin, interferon, doxorubicin, and fluorouracil [PIAF] or doxorubicin plus cisplatin) in HCC patients.
20,21
Median overall survival rates of 8.9 and 7.3 months and SD rates of 28% and 16%, respectively, for PIAF and doxorubicin/cisplatin regimens were reported.
20,21 Despite differences in study designs, our results are not unlike median overall survival results from a recent randomized phase III trial by Yeo et al 22 in HCC of doxorubicin versus PIAF; 6.8 and 8.7 months for doxorubicin and PIAF arms, respectively). A notable difference in the Yeo et al trial is the higher rate of HBV, which is consistent with an Asian population. There is also evidence that sorafenib may be combined successfully with other agents in HCC on the basis of a strong preclinical rationale and a favorable toxicity profile. Efficacy was demonstrated in a phase I combination study with sorafenib and doxorubicin in advanced HCC patients (one PR, one unconfirmed PR, and 61% SD).
23
There is poor correlation between TN and conventional methods of response assessment, which poses questions of how best to quantify efficacy of sorafenib. Despite tumors' increasing in size, the observation of TN in this study is intriguing. Although the usefulness of TN in assessing efficacy of anticancer agents in HCC remains to be established, it is a potentially significant clinical end point that warrants further investigation. However, the relationship between tumor necrosis and clinical outcome remains to be determined.
Relatively infrequent dose-limiting toxicities were observed. Notable grade 3/4 adverse events included fatigue, diarrhea, and HFS, which are commonly associated with sorafenib. 11 The interpatient PK differences between CP A and B patients were not clinically relevant, because sorafenib was equally well tolerated by these two subgroups, and exposure values were similar to those reported in phase I studies that showed no relationship between PK variability and toxicity.
11
Importantly, it is unlikely that dose adjustment would be necessary when administering sorafenib to patients with mild (CP A) or moderate (CP B) hepatic insufficiency.
Several biomarkers have been shown to have potential predictive significance in HCC. 24, 25 Because the Raf/MEK/ERK pathway has a role in HCC, and is targeted by sorafenib, pERK may be a useful biomarker. Staining was most intense in nuclei of tumor cells in this study, consistent with translocalization of pERK to the nucleus after activation. 26 Furthermore, HCC patients whose tumors expressed higher baseline pERK levels had a longer TTP following treatment with sorafenib. These data suggest that tumors containing higher levels of pERK are more sensitive, or responsive, to sorafenib.
WBCs and peripheral blood mononuclear cells, the main sources of RNA isolated from whole blood, are considered a "surrogate tissue" relative to a primary tumor or metastasis. 25 Therefore, geneexpression patterns of WBCs and peripheral blood mononuclear cells can be a molecular signature of a tumor that provides information on histologic stage or potential to respond to treatment. Although the RNA expression data from this study are encouraging, functional roles remain to be elucidated for the panel of genes that distinguished nonprogressors from progressors.
Cell-based and genomic analyses will undoubtedly advance the discovery of new biomarkers for HCC, and help refine inclusion criteria and patient selection. Analysis with a larger number of patients in a placebo-controlled trial is required to validate whether components identified in this study may be used prospectively to predict response to sorafenib. Evaluation of sorafenib in combination with cytotoxic agents in HCC is ongoing. 
